Arena Pharmaceuticals, Inc. (ARNA) Reaches $25.06 After 3.00% Down Move; HYPERDYNAMICS CORPORATION (HDYN) Shorts Decreased By 0.38%

November 14, 2017 - By Marie Mckinney

The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a huge mover today! About 252,123 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has declined 11.92% since November 14, 2016 and is downtrending. It has underperformed by 28.62% the S&P500.The move comes after 7 months negative chart setup for the $983.94M company. It was reported on Nov, 14 by Barchart.com. We have $24.31 PT which if reached, will make NASDAQ:ARNA worth $29.52M less.

HYPERDYNAMICS CORPORATION (OTCMKTS:HDYN) had a decrease of 0.38% in short interest. HDYN’s SI was 344,400 shares in November as released by FINRA. Its down 0.38% from 345,700 shares previously. With 281,300 avg volume, 1 days are for HYPERDYNAMICS CORPORATION (OTCMKTS:HDYN)’s short sellers to cover HDYN’s short positions. About 51,632 shares traded. Hyperdynamics Corporation (OTCMKTS:HDYN) has 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.

Hyperdynamics Corporation is an independent gas and oil exploration firm with prospects in offshore Republic of Guinea in Northwest Africa pursuant to rights granted to the Company by Guinea (the Concession) under a Hydrocarbon Production Sharing Contract (PSC). The company has market cap of $4.12 million. The Company’s primary focus is the advancement of exploration work in Guinea. It currently has negative earnings. The Company, through its subsidiary, SCS Corporation Ltd, conducts international gas and oil exploration activities in Guinea.

Analysts await Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report earnings on March, 13. They expect $-0.64 earnings per share, down 140.00% or $2.24 from last year’s $1.6 per share. After $-0.65 actual earnings per share reported by Arena Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -1.54% EPS growth.

Among 7 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Arena Pharmaceuticals had 13 analyst reports since October 28, 2015 according to SRatingsIntel. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Sector Perform” rating given on Wednesday, November 11 by RBC Capital Markets. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Tuesday, July 11 with “Buy” rating. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given on Wednesday, July 19 by Cantor Fitzgerald. Needham maintained the shares of ARNA in report on Tuesday, August 8 with “Hold” rating. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) earned “Outperform” rating by FBR Capital on Thursday, September 15. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given on Wednesday, November 8 by Cantor Fitzgerald. As per Thursday, June 29, the company rating was maintained by Cantor Fitzgerald. WallachBeth Capital maintained the stock with “Buy” rating in Wednesday, October 28 report. The rating was maintained by Citigroup with “Buy” on Wednesday, July 12. Leerink Swann maintained it with “Buy” rating and $5300 target in Monday, July 17 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com